- PharmaLogic has opened a new PET radiopharmaceutical manufacturing facility in Atlanta, Georgia, as part of a $250 million investment to expand U.S. infrastructure.
- The facility will support production, R&D, and distribution of radiopharmaceuticals, contributing to a network delivering over 2.5 million doses annually.
PharmaLogic Holdings Corp. announced the opening of a new PET radiopharmaceutical manufacturing facility in Atlanta, Georgia, expanding its contract development and manufacturing organization (CDMO) capabilities in the United States. The facility is part of a broader $250 million investment aimed at strengthening domestic radiopharmaceutical infrastructure and improving patient access to diagnostic and therapeutic products.
The Atlanta site is equipped with PET manufacturing technology to support production and research activities. It is designed to increase manufacturing capacity while providing dedicated resources for the development of new radiopharmaceuticals. The facility’s location is intended to enable timely distribution of radiopharmaceuticals to hospitals and imaging centers across the Southeast.
“The opening of our Atlanta facility marks another critical step in our $250 million investment to address the deficit of radiopharmaceutical infrastructure in the U.S.”
Etienne Montagut, President and CEO of PharmaLogic
The new facility adds to PharmaLogic’s growing network, which includes recent site openings in Cincinnati, Ohio; the Bronx, New York; Salt Lake City, Utah; and Los Angeles, California. The company stated that its expanding platform supports both production and development activities within its contract manufacturing operations.
PharmaLogic reported that its global network currently delivers more than 2.5 million doses annually. The company indicated that its expansion strategy is focused on increasing manufacturing and distribution capabilities to support broader access to radiopharmaceutical therapies.
